Altimmune’s pemvidutide achieved a statistically significant reduction in heavy drinking days compared to a placebo in a Phase 2 trial. This peptide drug, which is designed to activate the GLP-1 and glucagon receptors, is also on track to begin a pivotal test in the fatty liver disease MASH. The post Altimmune’s GLP-1 Drug Reduces Heavy Drinking in Alcohol Use Disorder Trial appeared first on MedCity News .
California lawmakers gave public school teachers 14 weeks of paid leave in the state’s new budget, a long-sought benefit for the largely female workforce. Gov. Gavin Newsom previously opposed similar measures.
The government will cap how much graduate students may borrow in federal loans. The new policy could leave many at the mercy of private lenders with higher interest rates. The borrowing limits will affect students pursuing expensive healthcare careers, and some worry they may impede efforts to diversify the healthcare workforce.
The recent outbreak of a foodborne parasite sickened thousands and hospitalized hundreds across the U.S. before federal investigators identified the suspected source. Food safety experts say cuts to the public health system hobbled the response — and that the next outbreak could be much worse.
Done well, NICU UM is so much more than an approval process. It is a clinical credibility engine that — when integrated with Case Management (CM) — drives every NICU admission toward the most appropriate, impactful care. The post Why Specialized UM Delivers on Every NICU Outcome appeared first on MedCity News .
A few minutes of interaction with a digital tablet and speaking can reveal patterns that once required advanced imaging, years of observation, or were just completely undetectable. The post Spotting Alzheimer’s Years Earlier Through AI and Clinically Meaningful Insights appeared first on MedCity News .
Lakshmi Halasyamani, chief clinical officer at Endeavor Health, thinks value-based care isn’t really about payment models. To her, this work centers on understanding patients’ clinical, social and financial circumstances well enough to make care plans that actually work for their lives. The post Why Endeavor Health Refuses to Silo Its Value-Based Care Strategy appeared first on MedCity News .
Argenx’s first acquisition is the buyout of Forte Biosciences, a company with a lead drug that has early clinical validation in celiac disease and vitiligo. Argenx executives say this antibody complements its blockbuster product Vyvgart, offering a different mechanism of action but similar pipeline-in-a-product potential. The post Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook to Prevalent Disorders appeared first on MedCity News .
When staff are overextended and patients face delays or abandon care, the issue is no longer a narrow administrative burden. It becomes a business, financial, and access challenge that demands a different operating model. The post Prior Authorization Is Draining Revenue: Why Automation Has Become a Strategic Imperative appeared first on MedCity News .
The question is not whether the technology is impressive. The question is whether it shows up at the right time, with the right information, inside the workflow where the decision is being made. Anything else is just another report. The post How AI Inside Clinical Workflows Is Unlocking Patient Throughput appeared first on MedCity News .
[Sponsored] On a recent webinar sponsored by Verato, panelists from SCAN Health Group and the Alliance of Community Health Plans discussed how their organizations are meeting the moment. The post AI Readiness Starts with Solving Healthcare’s Data Fragmentation Problem appeared first on MedCity News .
As patients increasingly bring AI chatbot advice into exam rooms, where does liability land when that advice goes wrong? Health law attorney Meghan O’Connor said the answer still isn’t clear, but silence is the riskiest response for providers. The post What Happens When Patients Trust AI Over Their Doctor? appeared first on MedCity News .